Proteins and Peptides
2 December 2014
Preclinical Data Published on AM-Pharma’s recAP to Treat Ultra Rare Disease Hypophosphatasia1 December 2014
Baxter Submits Application for U.S. FDA Approval of BAX 855, Extended Half-Life Recombinant FVIII Based on ADVATE for Hemophilia A28 November 2014
Ipsen Announces FDA Acceptance of Filing for Dysport® in the Treatment of Upper Limb Spasticity in Adult Patients25 November 2014
Researchers Report Thymosin Beta 4 is Cardioprotective in Pulmonary Hypertension/Heart Failure Model24 November 2014
Novartis drug Signifor® approved in EU, marking an advance for patients with inadequately controlled acromegaly21 November 2014
Victoza(R) receives positive CHMP opinion for use in adults with type 2 diabetes and moderate renal impairment21 November 2014
Proteo, Inc. / Proteo Biotech AG: Final Analysis of the Phase II Clinical Study on Elafin in Coronary Artery Bypass Surgery Completed18 November 2014
CKD Pharmaceuticals achieves tolerated well, and showed a comparable PK, PD, and tolerability profile to that of NESP® (Darbepoetin alfa).17 November 2014
DiaMedica Announces Top-line Results of Phase IIa Clinical Trial of DM199 for Type 2 Diabetes17 November 2014
Allena Pharmaceuticals Presents Phase 1 Data on ALLN-177 at American Society of Nephrology Kidney Week 201417 November 2014
Zealand advances its proprietary stable glucagon analogue for severe hypoglycemia in diabetes into clinical development11 November 2014
Synageva BioPharma Presents New Data From Phase 3 Study Of Sebelipase Alfa In Children And Adults With LAL Deficiency At The AASLD Meeting4 November 2014
D-Pharm reports first results from its Phase 2 clinical study of THR-18 in acute stroke patients treated with tPA3 November 2014
Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of EBI-005 in Patients with Dry Eye Disease3 November 2014
Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints28 October 2014
Apogenix – Positive Results from APG101 Phase II Clinical Trial Published in Clinical Cancer Research28 October 2014
PROMETIC LIFE SCIENCES INC. PROMETIC’S PLASMINOGEN IND AND CLINICAL PROGRAM CLEARED BY FDANews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports